Tigermed EMEA represents the European, Middle East, and Africa division of the global Tigermed Group – a full-service CRO with international coverage, supporting the development of pharmaceuticals and medical devices across all phases of clinical research. With rapid expansion throughout the EMEA region and a growing project portfolio, the company has strengthened its position as a strategic partner for sponsors aiming to accelerate therapy development and achieve efficient market access.
According to public company data, Tigermed EMEA has a strong and well-structured presence:
operations in over 20 EMEA countries,
15 local offices,
a team of 160+ specialists across Europe,
experience in over 200 Phase I–IV clinical studies conducted in the region.
At the group level, Tigermed considers EMEA a strategic pillar, with over 100 multi-regional clinical trials (MRCT)conducted in Europe and involvement in more than 210 clinical projects by 2025.
The Tigermed EMEA portfolio includes studies across various therapeutic areas: oncology, endocrinology/metabolic diseases, neurology (CNS), infectious diseases, cardiovascular, rheumatology, and ophthalmology — including complex multi-country projects.
Tigermed EMEA has demonstrated experience in managing large-scale vaccine trials, supported by Tigermed’s global infrastructure.
At the group level, Tigermed has contributed to COVID-19 vaccine programs by conducting accelerated multi-regional studies, directly supporting rapid approval pathways.
Global Tigermed reports highlight:
567 drug studies and
341 medical device projects conducted in a single year,
as well as direct contributions to the approval of:
three innovative medical devices,
two AI-based medical software solutions,
and support in achieving market approval for a new CGRP receptor antagonist for migraine, in collaboration with a global sponsor.
Tigermed EMEA played a key role in the European components of these programs, contributing operational, regulatory, and pharmacovigilance expertise.
Tigermed is a pioneer in DCT, implementing:
hybrid studies with ePRO,
telemedicine,
digital tools for remote data collection,
home IMP delivery,
and fully digital study management.
Notably, Tigermed implemented a DCT component for the Nurtec® migraine study, enabling digital data collection.
Tigermed EMEA integrates these practices across Europe, adapting them to CTR and local regulatory requirements.
Tigermed and Tigermed EMEA collaborate with organizations such as Purpose Africa and Africare to:
expand clinical site networks,
increase patient access to trials,
develop local research infrastructure,
and support multi-regional studies across African regions.
This initiative helps sponsors include diverse patient populations and access emerging markets.
Tigermed EMEA has extensive experience in:
oncology (including cell and gene therapies),
metabolic diseases,
infectious diseases,
cardiovascular diseases,
neurological and rheumatological disorders.
traditional vaccines (influenza, HPV, etc.),
innovative vaccine platforms, including COVID-19.
implantable and non-implantable devices,
medical software and AI-based solutions,
performance and safety studies under MDR/IVDR.
efficacy evaluations,
post-marketing observational studies.
Including:
feasibility,
site selection,
project management,
data management & statistical analysis,
regulatory support (CTR, MDR, IVDR),
and integrated pharmacovigilance.
Tigermed EMEA’s results translate into clear advantages for partners:
Reduced risk and accelerated approval timelines, supported by proven experience in hundreds of studies.
An extensive network of clinical sites across 20+ countries, ideal for MRCT.
Strong expertise in large vaccine studies, medical devices, and AI-enabled solutions, rapidly growing segments.
A unique ability to combine global capabilities with local expertise across EMEA.
Implementation of modern technologies (DCT, ePRO, telemedicine) for superior operational efficiency.